Provider Education & Utilization Initiatives Alliance of States with PMPs East Regional Meeting

Similar documents
4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Arkansas Department of Health

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Ontario s Narcotics Strategy

Report to the Legislature: Unsolicited Reporting Criteria Established and Process Review MN Prescription Monitoring Program

New Mexico. Prescribing and Dispensing Profile. Research current through November 2015.

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.

Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015.

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.

Project Update: Comparing South Dakota Prescription Drug Monitoring Program Law Enforcement Profile Requests to Criminal History Data

North Dakota Board of Pharmacy

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Substance use and misuse

Prescription Drug Monitoring Programs and Other State-Level Strategies

VIRGINIA S OPIOID & HEROIN OVERDOSE EPIDEMIC

WHAT YOU NEED TO KNOW TO ABOUT AB 474

Opioid Abuse in Iowa Rx to Heroin. Iowa Governor s Office of Drug Control Policy January 2016

ANNUAL REPORT

Prescription Monitoring Program Center for Excellence, Brandeis University. April 10-12, 2012 Walt Disney World Swan Resort

Effective Date: May 19, Revised Date: August 18, Policy Number: MED Policy 313. Pain Management Long Term Opioid Use

Evaluation of the N.C. Prescription

Our Journey to Addressing the PA PDMP Program. Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System

ISSUING AGENCY: Regulation and Licensing Department - NM Board of Osteopathic Medical Examiners.

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program

Prescription Opioid Overdose in Oregon: A public health perspective

Report to the Legislature: Recommendations on Required Use and Other Uses of the MN Prescription Monitoring Program Database

Maine PMP Update. Daniel Eccher, MPH MPA Convention May 20, 2011

Curbing Prescription Drug Abuse in Medicaid

Utah. Prescribing and Dispensing Profile. Research current through November 2015.

Oregon s PDMP: An epidemiological assist tool

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

California. Prescribing and Dispensing Profile. Research current through November 2015.

PRESCRIBING GUIDELINES

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Rural Prevention and Treatment of Substance Abuse Toolkit

Confronting the Opioid Epidemic

Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy. Date Prescription will Start Denying at the

Key Findings and Recommendations from the

4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update

Role of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx

State of California Department of Justice. Bureau of Narcotic Enforcement

Prescription Drugs: Issues in Treatment, Supervision and Case Management

Prescription Drug Monitoring Program (PDMP)

The Wisconsin Prescription Drug Monitoring Program

Michigan Legislative and Regulatory Pharmacy Initiatives Update

The Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division

Prescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017

OPIOID OVERDOSE EPIDEMIC: What Healthcare Providers Need to Know

Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine

Oregon Prescription Drug Monitoring Program

Addiction, Pain, & Public Health website -

Prescription Drug Monitoring Program (PDMP) Delaware. Information contained in this presentation is accurate as of November 2017

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

Medicaid Perspective

RX Drug Abuse Prevention in Nevada

Medicare Advantage Outreach and Education Bulletin

Managing Risks Associated with Doctor Shopping and Other Drug-Seeking Behaviors

Potential Solutions to Epidemic Substance Abuse in US and Europe

COLORADO PRESCRIPTION DRUG MONITORING PROGRAM

PDMP Tools to Identify Red Flag Situations

The Role of the PDMP: Foundational Knowledge and Best Practices

Morrison County Community-Based Care Coordination. Our Core Values Reverence Integrity Compassion Excellence

Opioid Prescribing Improvement Program

STATES RESPONSES TO MAIL ORDER PHARMACIES DELIVERING OR DISPENSING PRESCRIPTION DRUGS INTO THEIR STATES

Controlled Substances: A survey of tools and resources required by hospital pharmacists

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

State and Local Policies Regarding IDUs' Access to Sterile Syringes December 2005

Request for Proposals (RFP) for School-Based Screening, Brief Intervention, and Referral to Treatment (SBIRT) Services

North Carolina, like the rest of the nation, has been experiencing

What is harm reduction?

Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good

Missouri Guidelines for the Use of Controlled Substances for the Treatment of Pain

PREVENTING PRESCRIPTION DRUG ABUSE AND OVERDOSE JUNE 23, 2016 SHERRY L. GREEN

Ahsan U. Rashid, M.D., F.A.C.P.

October 20, 2016 Scott K. Proescholdbell, MPH. Opioid Overdose and North Carolina s Public Health and Prevention Strategies

A Community Response to a Community Crisis

West Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Vermont. Prescribing and Dispensing Profile. Research current through November 2015.

Medicare Advantage Outreach and Education Bulletin

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3)

Practice Direction Refill History Recording System

ACCG Mental Health Summit

Amy Larrick Chavez-Valdez, Director, Medicare Drug Benefit and C & D Data Group

New York. Prescribing and Dispensing Profile. Research current through November 2015.

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4)

Arizona State Office of Rural Health Webinar Series

Best Practices and Foundation Forum. Fred Wells Brason II

Using PDMP Data to Guide Interventions with Possible At-Risk Prescribers

Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD

September 22, National Association of Attorneys General 1850 M Street, NW, 12 th Floor Washington, DC Prescription Opioid Epidemic

The Future of Prevention: Addressing the Prescription Drug Abuse and the Opioid/Heroin Epidemic in our Country

HOW TO DOCUMENT DOMESTIC VIOLENCE

The CARA & Buprenorphine Prescribing for APNs & PAs

NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)

Meth and Opioid Abuse Prevention Efforts

On December 27, 2017, the Lieutenant Governor signed into law several new requirements

Prescription Monitoring Program Center of Excellence at Brandeis. Drug-Related Deaths in Virginia: Medical Examiner Use of PMP Data

State, District, or Territory Criteria for Mandatory Enrol ment or Query of PDMP

Transcription:

Provider Education & Utilization Initiatives Alliance of States with PMPs East Regional Meeting Baltimore, MD April 5, 2011 Massachusetts Department of Public Health MA Prescription Monitoring Program

MA Prescription Monitoring Program Background Benefits of Utilization Current Initiatives to Increase Utilization Education on Recent Regulations Provider Education on Use of PMP Information Plans for Future

MA PMP Overview of Current Program Established by joint regulations Drug Control Program Board of Registration ti in Pharmacy Collects data on Schedule II - V (e.g., narcotics, stimulants, t sedatives) prescriptions dispensed d by community, clinic and outpatient pharmacies weekly (since Jan 2011) 3.5 million Schedule II prescriptions monitored in FY 10

MA PMP Overview of Current Program cont. Data reviewed and analyzed by PMP staff Solicited and Unsolicited Reports two user groups regulatory boards; law enforcement health care providers Medical Review Group (physicians, dentists, pharmacists) provides advice and consultation PMP Advisory Council advises on protocols and implementation

MA PMP Utilization Benefits Wider use of the PMP will promote (1) heightened awareness of potential for drug abuse or diversion, (2) need to screen for risk factors: past cocaine, alcohol, cannabis use; lifetime history of substance use disorder; family history of substance abuse; history of legal problems involving drug or alcohol abuse; tobacco dependence; history severe depression or anxiety Attribution: Daniel Alford, MD, MPH, Associate Professor of Medicine, Boston,,,, University School of Medicine, Boston Medical Center

MA PMP Utilization Initiatives Current Targeted enrollment process Live enrollment at programs, conferences In-person trainings Promotion in MA CSR renewals/recalls

MA PMP Utilization Initiatives Current cont. Provider Champions MA Unsolicited Provider Reports Current cover letter provides information on MA Online PMP on-line provider look-ups and alerts Electronic Provider Reports Non-Enrollee Notice Letter to provider informing of alert and how to enroll in Online PMP to obtain specific patient information

MA Online PMP Unsolicited Report Notice From: dcp.dph@state.ma.us To: jsmith@medicaloffice.com Subject: MA Online PMP Drug Utilization Report Massachusetts Department of Public Health Online Prescription Monitoring Program Drug Utilization Report Record ID: 123456789 This is to inform you that, according to an analysis of the records of the Massachusetts Online Prescription Monitoring Program (Online PMP), a patient to whom you have prescribed or dispensed a controlled substance appears to have obtained prescriptions for controlled substances from multiple sources and in potentially harmful quantities.

MA PMP Provider Education *Regulations Promulgated in August 2011 Traditional C.E. Programs for Pharmacists Pharmacy Associations Colleges of Pharmacy Web based program PMP Website Handbook for the Pharmacist ac & Pharmacy acy Software Provider Massachusetts PMP Pharmacy FAQ

MA PMP Provider Education Initiatives Ongoing Toolkits Accompanying each unsolicited report to prescribers and dispensers Screening, Brief Intervention, Referral and Treatment (SBIRT) Further development Working with Addiction Technology Transfer Center (ATTC) Collaboration with medical and pharmacy schools Enhancing SBIRT Screening, Brief Intervention, Referral and Treatment Working with MA Bureau of Substance Abuse Services

MA PMP Provider Education Unsolicited Reports TOOLKIT Unsolicited reports have been sent to prescribers since Jan. 2010 Unsolicited reports to pharmacies (pharmacists) in the near future Access to TOOLKIT on Alliance website Access to TOOLKIT on Alliance website (www.pmpalliance.org)

TOOLKIT cont. Purpose Determine possible aberrant/questionable behavior Opportunities for communication Provide information on prescribing and dispensing of other controlled substances Limitations of data Prescription does not belong to individual of concern Prescriptions could be missing from report Prescriptions attributed to wrong prescriber

TOOLKIT Highlights Overview - Responding to Concerning Activity it PMP report should not be interpreted in isolation from other pertinent patient data such as History of substance abuse Physical signs of current substance abuse Urine screen Consultations with other providers Early refills, lost prescriptions..

TOOLKIT Highlights cont. Overview - Responding to Concerning Activity it SBIRT Screening Non-judgmental discussion with patient It s difficult to confront a patient t on a hunch h or a feeling but having the PMP data report provides an opening for discussion, in a nonjudgmental way. - James Wechsler, MD, PhD Is there a diagnosis? Under-treatment of pain Change in medical condition Is there a reason? Administrative change in care Person did not understand directions

TOOLKIT Highlights cont. Overview - Responding to Concerning Activity it SBIRT Brief Intervention Discuss concerns Interaction with other medications Hinder improvement of medical condition How prescription drug abuse begins Overlapping/ Early refills Negative effects family, employment, legal

TOOLKIT Highlights cont. Overview- Responding to Concerning Activity it Discuss expectations and next steps only one prescriber Increase monitoring dosage counts, urine tests SBIRT RT = Referral and Treatment t Pain specialist or Addiction management

TOOLKIT Highlights cont. Overview - Responding to Concerning Activity it What if provider suspects criminal activity e.g., dr. shopping, forgeries Contact L.E. authorities What if provider concerned about other providers on report? Contact professional boards

MA PMP Provider Education Initiatives Planning Working with Addiction Technology Transfer Center (ATTC) Collaboration with medical and pharmacy schools Enhancing SBIRT Screening, Brief Intervention, Referral and Treatment Working with MA Bureau of Substance Abuse Services

Addictions Technology Transfer Center Raise awareness of evidence-based and promising treatment and recovery service practices, Build skills to prepare the workforce to deliver state-of-the-art addictions treatment and recovery services, Change practice by promoting incorporation of these new skills into everyday use for the purpose of improving ing addictions treatment and recovery outcomes. For more info: ATTCnetwork.org

MA PMP Acknowledgement Portions of this project were supported by grants awarded by the U.S. Bureau of Justice Assistance. Points of view or opinions in this presentation are those of the author and do not represent the official position or policies i of the United States Department of Justice.

Thank you, Adèle Adèle Audet, R.Ph. Assistant Director Drug Control Program 617-983-6721 6721 Adele.Audet@state.ma.us

Green Monster says Hello Orioles